Newsroom

Sputnik V authorized in Bangladesh

Moscow, April 27, 2021 – The Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund) announces that the Directorate general of Drug Administration (DGDA) under the Ministry of Health & Family Welfare of the People's Republic of Bangladesh has approved the use of the Russian Sputnik V vaccine against coronavirus.

The vaccine has been registered under the emergency use authorization procedure (EUA). Bangladesh has become the 62-nd country to authorize the use of Sputnik V. Total population of the countries where Sputnik V is approved for use is 3.2 billion people.

Post-vaccination studies in a number of countries demonstrate that Sputnik V is the safest and most effective vaccine against coronavirus. Sputnik V ranks second among coronavirus vaccines globally in terms of the number of approvals issued by government regulators.

Sputnik V has also been approved in Russia, Belarus, Argentina, Bolivia, Serbia, Algeria, Palestine, Venezuela, Paraguay, Turkmenistan, Hungary, UAE, Iran, Republic of Guinea, Tunisia, Armenia, Mexico, Nicaragua, Republika Srpska (entity of Bosnia and Herzegovina), Lebanon, Myanmar, Pakistan, Mongolia, Bahrain, Montenegro, Saint Vincent and the Grenadines, Kazakhstan, Uzbekistan, Gabon, San-Marino, Ghana, Syria, Kyrgyzstan, Guyana, Egypt, Honduras, Guatemala, Moldova, Slovakia, Angola, Republic of the Congo, Djibouti, Sri Lanka, Laos, Iraq, North Macedonia, Kenya, Morocco, Jordan, Namibia, Azerbaijan, Philippines, Cameroon, Seychelles, Mauritius, Vietnam, Antigua and Barbuda, Mali, Panama, India and Nepal.

Kirill Dmitriev, CEO of the Russian Direct Investment Fund, said:

“Bangladesh is one of the most populated countries in Asia and with the help of Sputnik V many lives will be saved in the country. Diversification of the national vaccine portfolio through registration of Sputnik V provides people of Bangladesh with access to one of the best vaccines against coronavirus in the world, which has been approved in over 60 countries.”

Sputnik V has a number of key advantages:

  • Efficacy of Sputnik V is 97.6% based on the analysis of data on the coronavirus infection rate among those in Russia vaccinated vaccinated with both components of Sputnik V from December 5, 2020 to March 31, 2021;

  • The Sputnik V vaccine is based on a proven and well-studied platform of human adenoviral vectors, which cause the common cold and have been around for thousands of years.

  • Sputnik V uses two different vectors for the two shots in a course of vaccination, providing immunity with a longer duration than vaccines using the same delivery mechanism for both shots.

  • The safety, efficacy and lack of negative long-term effects of adenoviral vaccines have been proven by more than 250 clinical studies over two decades.

  • There are no strong allergies caused by Sputnik V.

  • The storage temperature of Sputnik V at +2+8 C means it can be stored in a conventional refrigerator without any need to invest in additional cold-chain infrastructure.

  • The price of Sputnik V is less than $10 per shot, making it affordable around the world.

***

Russian Direct Investment Fund (RDIF) is Russia's sovereign wealth fund established in 2011 to make equity co-investments, primarily in Russia, alongside reputable international financial and strategic investors. RDIF acts as a catalyst for direct investment in the Russian economy. RDIF’s management company is based in Moscow. Currently, RDIF has experience of the successful joint implementation of more than 80 projects with foreign partners totaling more than RUB2 tn and covering 95% of the regions of the Russian Federation. RDIF portfolio companies employ more than 800,000 people and generate revenues which equate to more than 6% of Russia’s GDP. RDIF has established joint strategic partnerships with leading international co-investors from more than 18 countries that total more than $40 bn. Further information can be found at www.rdif.ru

For additional information contact:

Alexey Urazov
Russian Direct Investment Fund
Director for External Communications

Mobile: +7 915 312 76 65
E-mail: [email protected]

Andrew Leach / Maria Shiryaevskaya
Hudson Sandler

Tel: +44 (0) 20 7796 4133

Message has been successfully sent!

Thank you!
You have been subscribed